Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents
作者:Mohamed Ayman El-Zahabi、Helmy Sakr、Khaled. El-Adl、Mohamed Zayed、Adel S. Abdelraheem、Sally I. Eissa、Hazem Elkady、Ibrahim H. Eissa
DOI:10.1016/j.bioorg.2020.104218
日期:2020.11
12 to 76.91 µM). The most active compounds were further evaluated for their in vitro immunomodulatory activities via estimation of human tumor necrosis factor alpha (TNF-α), human caspase-8 (CASP8), human vascular endothelial growth factor (VEGF), and nuclear factor kappa-B P65 (NF-κB P65) in HCT-116 cells. Thalidomide was used as a positive control. Compounds 33h and 42f showed a significant reduction
沙利度胺及其类似物是免疫调节药物,可抑制某些与癌症相关的炎性介质的产生。在目前的工作中,设计并合成了一系列新的沙利度胺类似物以获得新的有效抗肿瘤免疫调节剂。评估合成的化合物对四种癌细胞系(HepG-2,HCT-116,PC3和MCF-7)的细胞毒性活性。化合物33 ħ,33我,42 ˚F和42 ħ表现出较强的效力针对与IC所有测试的细胞系中50个值范围从14.63到49.90μM比得上的沙利度胺(IC 50值范围从32.12到76.91 µM)。通过评估人类肿瘤坏死因子α(TNF-α),人类caspase-8(CASP8),人类血管内皮生长因子(VEGF)和核因子kappa-B ,进一步评估了活性最高的化合物的体外免疫调节活性。P 65(NF-κB P 65)中的HCT-116细胞。沙利度胺用作阳性对照。化合物33 ħ和42 ˚F显示出TNF-α一个显著减少。此外,化合物33 i和42 f